Duke Prostate Center, Durham, NC, USA.
Prostate Cancer Prostatic Dis. 2010 Jun;13(2):108-16. doi: 10.1038/pcan.2009.62. Epub 2010 Jan 12.
In 2009, castration-resistant metastatic prostate cancer continues to account for more deaths in US men than any other cancer apart from lung cancer. Although novel targeted molecular, hormonal and immunologic agents are accelerating in their development in this disease, docetaxel and prednisone remain the standard palliative regimen for the majority of men who have progressed despite hormonal therapies. Thus, understanding the practical and often subtle issues of docetaxel initiation, duration of therapy, cessation of therapy and treatment holidays is critical for the informed use of this US Food and Drug Administration-approved regimen. In this review we address these topics in light of prognostic and predictive factors to help guide the rational use of docetaxel chemotherapy in men with this aggressive disease.
2009 年，去势抵抗性转移性前列腺癌导致的死亡在美国男性中仍高于除肺癌以外的其他任何癌症。尽管在这种疾病中，新的靶向分子、激素和免疫制剂的研发正在加速，但对于大多数尽管接受了激素治疗仍进展的男性，多西他赛和泼尼松仍然是标准的姑息治疗方案。因此，了解多西他赛起始、治疗持续时间、停止治疗和治疗间歇期的实际和经常微妙的问题，对于合理使用这种经美国食品和药物管理局批准的方案至关重要。在这篇综述中，我们根据预后和预测因素来讨论这些问题，以帮助指导在这种侵袭性疾病中合理使用多西他赛化疗。
